Pharmaceutical Business review

FDA approves Auriga’s oral Liquadd for ADHD

The company has said that Liquadd will be launched during the second quarter of 2008.

Frank Greico, CEO of Auriga, said: “This new product further solidifies company’s commitment to enhance our product portfolio. Currently, we promote several of our products to psychiatrists and pediatricians, and Liquadd will be a highly synergistic addition to company’s current promotional efforts in these specialties.”